Coordinated Increase in Serum Platelet-Derived Growth Factor-BB and Transforming Growth Factor-β1 in Patients with Chronic Pancreatitis

Adrych, Krystian; Smoczyński, Marian; Stojek, Magdalena; Śledziński, Tomasz; Korczyńska, Justyna; Goyke, Elżbieta; Świerczyński, Julian

doi:10.1159/000330294

Cited by 15 publications

(8 citation statements)

References 40 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, we conducted the IPA and identified several molecules such as PDGFB and VEGFA resulting from the net effects of differentially expressed miRNAs in AIP. Previous studies have shown that serum PDGF-BB and VEGF levels were altered in CP and pancreatic cancer [37,38,39], but PDGF-BB levels in patients with CP or pancreatic cancer were not different from those in controls in this study. Serum cytokine profiles in patients with AIP are currently unknown.…”

Section: Discussioncontrasting

confidence: 79%

Comprehensive Analysis of Serum microRNAs in Autoimmune Pancreatitis

et al. 2015

View full text Add to dashboard Cite

Background/Aims: Autoimmune pancreatitis (AIP) is a rare disease that has recently emerged as a unique type of pancreatitis with a presumed autoimmune etiology. MicroRNA (miRNA) is a small non-coding RNA that targets multiple mRNAs. miRNAs might exist in serum in a stabilized form, suggesting its potential application as a biomarker. We here examined the miRNA expression profile in the serum of patients with AIP. Methods: miRNAs were prepared from serum samples of patients with various pancreatic diseases (AIP (n = 3, each before and after the steroid therapy), chronic pancreatitis (n = 5), pancreatic cancer (n = 5)) or healthy controls (n = 5). A human miRNA Oligo chip containing approximately 2,000 miRNAs was used to identify differentially expressed miRNAs. Ingenuity Pathway Analysis (IPA) was used for the integrated analysis of altered miRNAs. Results: Microarray analysis identified miRNAs highly expressed in the serum of patients with AIP: 13 miRNAs vs. CP, 204 miRNAs vs. pancreatic cancer, and 19 miRNAs vs. healthy controls. miR-150-5p was commonly upregulated in AIP compared to the other samples. IPA revealed the most biological processes affected by the steroid therapy including cellular development, cellular growth, and cell movement. Conclusion: Our results identified that miRNAs were differentially expressed in the serum of AIP patients.

show abstract

Section: Discussioncontrasting

confidence: 79%

Comprehensive Analysis of Serum microRNAs in Autoimmune Pancreatitis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Clinically evident chronic pancreatitis, like other chronic inflammatory conditions, can cause elevated platelet counts [25], and has been associated with higher serum TGF-β1 [8,9]. In addition, clinically evident chronic pancreatitis has been associated with approximately 6-fold higher risk of pancreatic cancer [10].…”

Section: Discussionmentioning

confidence: 99%

“…This possibility is supported by evidence that clinically diagnosed chronic pancreatitis is associated with both elevated serum TGF-β1 [8,9] and strongly increased risk of pancreatic cancer [10]. Although the role of subclinical pancreatic inflammation in pancreatic cancer etiology is less clear, it is plausible that subclinical pancreatic inflammation could also increase both serum TGF-β1 and risk of pancreatic cancer.…”

Section: Introductionmentioning

confidence: 99%

Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies

Jacobs

Newton

Silverman

et al. 2014

Cancer Causes Control

View full text Add to dashboard Cite

Purpose Clinically evident chronic pancreatitis is a strong risk factor for pancreatic cancer. A small Japanese cohort study previously reported that pre-diagnostic serum transforming growth factor-β1 (TGF-β1) concentration, a potential marker of subclinical pancreatic inflammation, was associated with higher risk of pancreatic cancer. We further explored this association in a larger prospective study. Methods Serum TGF-β1 concentrations were measured in pre-diagnostic samples from 729 pancreatic cancer cases and 907 matched controls from a cohort of Finnish male smokers (the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study) and two cohorts of U.S. men and women, the Cancer Prevention Study-II (CPS-II) and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Multivariable-adjusted odds ratios (ORs) were estimated using conditional logistic regression. Results Overall, serum TGF-β1 concentration was not associated with a clear increase in pancreatic cancer risk (OR=1.36, 95% confidence interval (CI), 0.98-1.88 for highest vs. lowest quintile, p trend = 0.20). However, this association differed significantly by follow-up time (p=0.02). Serum TGF-β1 concentration was not associated with risk during the first 10 years of follow-up, but was associated with higher risk during follow-up after 10 years (OR=2.13, 95% CI 1.23-3.68 for highest vs. lowest quintile, p trend=0.001). During follow-up after 10 years, serum TGF-β1 was associated with higher risk only in the ATBC cohort, although most subjects were from ATBC during this time period and statistical evidence for heterogeneity across cohorts was limited (p=0.14). Conclusions These results suggest that high serum TGF-β1 may be associated with increased risk of pancreatic cancer although a long follow-up period may be needed to observe this association.

show abstract

“…For example, it was shown to be increased in patients with oesophageal cancer 12 and patients with chronic pancreatitis. 13 In another study, it was shown to be decreased in patients with metabolic syndrome. 14 In cancer it could be postulated that in addition to enhancing angiogenesis, increased levels of PDGF-BB could benefit tumour growth via hepcidin suppression leading to both increased iron availability Membrane Transport Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia Correspondence to Professor V Nathan Subramaniam, Membrane Transport Laboratory, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia; Nathan.…”

Section: Nathan Subramaniam Daniel F Wallacementioning

confidence: 93%